Replimune Cash Ratio from 2010 to 2024

REPL Stock  USD 13.26  1.67  11.19%   
Replimune Cash Ratio yearly trend continues to be quite stable with very little volatility. The value of Cash Ratio is projected to decrease to 1.75. From the period between 2010 and 2024, Replimune, Cash Ratio regression line of its data series had standard deviation of  3.88 and standard deviation of  3.88. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
1.84126317
Current Value
1.75
Quarterly Volatility
3.87687602
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Replimune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Replimune's main balance sheet or income statement drivers, such as Interest Income of 935.8 K, Depreciation And Amortization of 2 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.44. Replimune financial statements analysis is a perfect complement when working with Replimune Valuation or Volatility modules.
  
Check out the analysis of Replimune Correlation against competitors.

Latest Replimune's Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of Replimune Group over the last few years. It is Replimune's Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Replimune's overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Slightly volatile
   Cash Ratio   
       Timeline  

Replimune Cash Ratio Regression Statistics

Arithmetic Mean7.28
Geometric Mean6.04
Coefficient Of Variation53.25
Mean Deviation3.59
Median10.37
Standard Deviation3.88
Sample Variance15.03
Range10.7968
R-Value(0.72)
Mean Square Error7.79
R-Squared0.52
Significance0
Slope(0.62)
Total Sum of Squares210.42

Replimune Cash Ratio History

2024 1.75
2023 1.84
2022 4.33
2021 5.1
2020 12.55
2019 5.01
2018 2.6

About Replimune Financial Statements

Replimune investors utilize fundamental indicators, such as Cash Ratio, to predict how Replimune Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Ratio 1.84  1.75 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:
Check out the analysis of Replimune Correlation against competitors.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.04)
Return On Assets
(0.27)
Return On Equity
(0.50)
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.